Clik here to view.
Modra Pharmaceuticals于2021 ASCO GU年会公布其转移性前列腺癌IIb期临床试验初步数据
阿姆斯特丹 Modra Pharmaceuticals (“Modra”)今日公布了其先导产品ModraDoc006/r正在进行的治疗转移性去势抵抗性前列腺癌(mCRPC)...
View ArticleClik here to view.
Seagen and Astellas Announce Presentation of Results from PADCEV® (enfortumab...
BOTHELL, Wash. & TOKYO Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced results from the second cohort (cohort...
View ArticleClik here to view.
Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival...
BOTHELL, Wash. & TOKYO Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced primary results from the phase 3...
View ArticleClik here to view.
MED™ 3Dプリントで製造した医薬品が米国FDAよりIND承認を取得
中国・南京 （ビジネスワイヤ） — 医薬品の3Dプリントを専門とする製薬企業のTriastek,...
View ArticleClik here to view.
Professor Juan Marchal Believes Propanc Biopharma’s Proenzyme Therapy May...
MELBOURNE, Australia Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
Boston Immune Technologies and Therapeutics and BeiGene Enter into an...
BOSTON & CAMBRIDGE, Mass. & BEIJING Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of novel antagonist antibodies for cancer and other diseases, and...
View ArticleClik here to view.
Genetron Health Reports Unaudited Fourth Quarter and Full Year 2020 Financial...
BEIJING Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests,...
View ArticleClik here to view.
Twist Bioscience and Kyowa Kirin Partner for GPCR Antibody Discovery
SOUTH SAN FRANCISCO, Calif. & LA JOLLA, Calif. Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its...
View ArticleClik here to view.
Propanc Biopharma Provides Upcoming Milestones
MELBOURNE, Australia Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
Rapid Medical Receives FDA Clearance for the First Adjustable Stent Retriever...
YOKNEAM, Israel & MIAMI Rapid Medical, developer of responsive, adjustable neurovascular devices, announces the FDA clearance of its TIGERTRIEVER™ revascularization device for use in the...
View ArticleClik here to view.
美国眼镜行业零售商Costco正式采购三井化学高折射率镜片单体MRTM
东京 (美国商业资讯)–美国眼镜行业零售商Costco（英文：Costco Wholesale Corporation，总部位于美国华盛顿州，CEO：W. Craig Jelinek）正式决定采购源于三井化学株式会社（总部位于东京都港区，董事长兼总经理：桥本修）所研发的高折射率镜片原材料MRTM所生产的镜片。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
European Medicines Agency Accepts Marketing Authorization Application for...
TOKYO & BOTHELL, Wash. Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced that a marketing authorization...
View ArticleClik here to view.
インサイト、線維芽細胞増殖因子受容体2（FGFR2）融合遺伝子を有し、がん化学療法後に増悪した切除不能胆道がん患者の治療薬としてのペマジール（ペミガチニブ...
米デラウェア州ウィルミントン （ビジネスワイヤ） — インサイト（Nasdaq:INCY）は本日、厚生労働省が選択的な線維芽細胞増殖因子受容体（FGFR）阻害薬のペマジール（Pemazyre®、ペミガチニブ）を、線維芽細胞増殖因子受容体2（FGFR2）融合遺伝子1を有し、がん化学療法後に増悪した切除不能胆道がん（BTC）患者の治療薬として承認したと発表しました。...
View ArticleClik here to view.
Mitsui Chemicals’ MR™ High Refractive Index Ophthalmic Lens Monomers Picked...
TOKYO Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu) today announced that its MR™ series of high refractive index lens monomers has been picked up and launched as the...
View ArticleClik here to view.
Clik here to view.
アルヴォテックはアッヴィによる最近の主張に疑義
アイスランド・レイキャビク （ビジネスワイヤ） — アルヴォテックのHUMIRA®（アダリムマブ）バイオシミラー候補であるAVT02に関するアッヴィの不正主張に対して、アルヴォテックは強く異議を提起しています。アルヴォテックは、このような嫌疑に対して精力的な防衛を行います。...
View ArticleClik here to view.
Alvotech对AbbVie最近的指控提出抗议
冰岛雷克雅未克 (美国商业资讯)–Alvotech强烈抗议AbbVie提出的有关AVT02不当行为的指控，AVT02是Alvotech拟开发的针对HUMIRA® （阿达木单抗(adalimumab)）的生物仿制药。Alvotech将针对上述指控进行积极辩护。...
View ArticleClik here to view.
AOP Orphan：对PharmaEssentia的仲裁裁决完全有效
奥地利维也纳 (美国商业资讯)–自2017年以来，PharmaEssentia多次试图终止与AOP Orphan之间就BESREMi® (Ropeginterferon alfa-2b)达成的协议。经过持续两年半的仲裁程序，国际商会仲裁庭于2020年10月就此案做出裁决。仲裁裁决指出，PharmaEssentia多次试图终止协议的行为是不合理的，AOP...
View ArticleClik here to view.
AOPオーファンが薬華医薬に対する仲裁裁定が完全に妥当であると報告
オーストリア・ウィーン （ビジネスワイヤ） — 2017年以後、薬華医薬はBESREMi®（ロペグインターフェロン...
View Article